The deal effectively removes SNTI's most advanced clinical asset (SENTI-202) from the public company, replacing it with highly contingent CVRs. The surviving public entity has very limited cash and early-stage programs only. Monitor stockholder vote and potential delisting risk; CVR milestone probabilities are highly uncertain. The $6M additional funding provides only a short runway.
Price Chart
Executive Summary
Senti Biosciences (SNTI) entered into a merger agreement with a Celadon affiliate to spin off its lead asset SENTI-202 into a private company, leaving SNTI as a public shell focused on early-stage Regulator Dial programs. SNTI stockholders will receive contingent value rights (CVRs) worth up to $60M in milestone payments tied to SENTI-202's development and commercialization. The company has only ~$6.5M cash and expects to add $6M from Celadon, funding operations only into Q4 2026.
Key Financial Metrics
Key Facts
- Merger with Celadon affiliate: Merger Sub merges into Midco, with Midco becoming a wholly owned subsidiary of Parent.
- SNTI stockholders receive one CVR per share, entitling them to pro-rata shares of up to $60M in milestone payments: $10M on BLA filing, $20M on FDA approval, $30M on cumulative net sales >$200M for SENTI-202.
- CVRs expire on the 7th anniversary of closing and are non-transferable except in limited circumstances.
- SNTI retains Regulator Dial platform, Rett syndrome program, and TIL program; all other assets (including SENTI-202) transfer to NewCo.
- Preliminary cash balance as of June 30, 2026: $6.5M; additional $6M funding from Celadon via convertible notes (subject to ATM offset).
- Transaction requires stockholder approval (majority of outstanding shares plus majority of minority vote). Outside date: December 31, 2026.
- Celadon already owns 54.6% of SNTI (pro forma after conversion of Initial Notes).
- All outstanding stock options and RSUs fully vest immediately prior to closing.
Financial Impact
Up to $60 million in contingent payments to SNTI stockholders over seven years, but no guaranteed cash consideration. SNTI's remaining cash of ~$6.5M plus $6M additional funding provides limited runway to Q4 2026.
Risk Factors
- CVR milestones may never be achieved, resulting in zero cash consideration for SNTI stockholders.
- SNTI's remaining cash is only sufficient to fund operations into Q4 2026; additional capital likely needed.
- Potential delisting from Nasdaq if listing requirements not met post-merger.
- Transaction is with a related party (Celadon, already controlling stockholder), raising governance concerns.
- Early-stage Regulator Dial programs face high clinical and regulatory risk.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 12 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (SNTI) — Batch item 1 | 0001628280-26-048249 |
| Exhibit: exhibit101-contingentvalue.htm | 0001628280-26-048248 |
| Exhibit: exhibit992-riskfactors.htm | 0001628280-26-048249 |
| Exhibit: exhibit991-pressrelease.htm | 0001628280-26-048248 |
| Document: snti2026entryintomerger202.htm | 0001628280-26-048249 |
| Document: 0001628280-26-048249-index-headers.html | 0001628280-26-048249 |
| Document: 0001628280-26-048249-index.html | 0001628280-26-048249 |
| Document: 0001628280-26-048249.txt | 0001628280-26-048249 |
| 8-K Filing (SNTI) — Batch item 9 | 0001628280-26-048248 |
| DEFA14A Filing (SNTI) — Batch item 10 | 0001628280-26-048249 |
| 8-K Data (Synthetic) | 0001628280-26-048249 |
| 8-K Data (Synthetic) | 0001628280-26-048249 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 8-K | $0.1926 | awaiting T+5 | — | $0.1750 (−9.14%) |
Oct 26, 2026 1d ago | 8-K | $0.1720 | awaiting T+5 | — | $0.1750 (−1.74%) |
Oct 13, 2026 14d ago | DEFA14A | $0.2408 $0.2175 | ▼ −9.68% | ▼ −10.13% | $0.1750 (−27.33%) |
Oct 13, 2026 14d ago | 8-K | $0.2408 $0.2175 | ▲ +9.68% | ▲ +10.13% | $0.1750 (+27.33%) |
Sep 25, 2026 4w ago | EFFECT | $0.3293 $0.3223 | ▲ +2.13% | ▲ +1.90% | $0.1750 (+46.86%) |
Sep 24, 2026 4w ago | DEFM14A | $0.3293 $0.3223 | ▲ +2.13% | ▲ +1.90% | $0.1750 (+46.86%) |
Sep 22, 2026 5w ago | S-3/A | $0.3156 $0.3075 | ▲ +2.57% | ▲ +1.38% | $0.1750 (+44.55%) |
Sep 10, 2026 6w ago | S-3/A | $0.3060 $0.3200 | ▼ −4.58% | ▼ −4.80% | $0.1750 (+42.81%) |
Sep 4, 2026 7w ago | DEFA14A | $0.3326 $0.3021 | ▼ −9.17% | ▼ −7.96% | $0.1750 (−47.38%) |
Sep 4, 2026 7w ago | 8-K | $0.3326 $0.3021 | ▲ +9.17% | ▲ +7.96% | $0.1750 (+47.38%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers